ArticleInvestigative ophthalmology & visual science2010
A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap.
Article in Investigative ophthalmology & visual science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).The British journal of ophthalmology · 2014Guideline
- Vascular remodeling of macular neovascularization following switch to intravitreal faricimab in neovascular AMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Critical roles of miR-21 in promotions angiogenesis: friend or foe?Clinical and experimental medicine · 2025Review
- Preclinical Retinal Disease Models: Applications in Drug Development and Translational Research.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview.Current diabetes reviews · 2025Review
- Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.Biomolecules · 2024Review
- Oxidative Stress and Antioxidants in Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2023Review
- Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits.Experimental eye research · 2022Article
- Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.International journal of molecular sciences · 2022Review
- Subretinal injection in mice to study retinal physiology and disease.Nature protocols · 2022Review
- Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration.Asian journal of pharmaceutical sciences · 2021Article
- Response to treatment with intravitreal anti-vascular endothelial growth factors in bilateral exudative cuticular drusen.American journal of ophthalmology case reports · 2021Article
- MicroRNAs in laser-induced choroidal neovascularization in mice and rats: their expression and potential therapeutic targets.Neural regeneration research · 2021Article
- In Vitro and In Vivo Evaluation ofBiomolecules · 2021Article
- A new rat model of treatment-naive quiescent choroidal neovascularization induced by human VEGF165 overexpression.Biology open · 2020Article
- Real-time OCT guidance and multimodal imaging monitoring of subretinal injection induced choroidal neovascularization in rabbit eyes.Experimental eye research · 2019Article
- In Situ Cross-linking Hydrogel as a Vehicle for Retinal Progenitor Cell Transplantation.Cell transplantation · 2019Article
- Secretogranin III as a novel target for the therapy of choroidal neovascularization.Experimental eye research · 2019Article
- Reliability and reproducibility of a rodent model of choroidal neovascularization based on the subretinal injection of polyethylene glycol.Molecular vision · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe exudative, or the wet form of age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). A subretinal Matrigel (BD Biosciences, Bedford MA) model of CNV is described here, along with the effects of vascular endothelial growth factor (VEGF) neutralization on the development of CNV and associated inflammation and fibrosis.
methodsCNV was induced in adult Sprague-Dawley rats by subretinal injection of Matrigel. CNV growth and associated leukocyte infiltration and collagen deposition were examined. VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a recombinant protein that comprises portions of the extracellular domains of VEGF receptors 1 and 2 and that binds all isoforms of VEGF-A as well as placental growth factor with high affinity, was administered subcutaneously.
resultsInitiation of CNV was detected 4 days after Matrigel injection and then increased progressively in size. Systemic administration of VEGF Trap beginning on day 2 and 6 completely prevented development of CNV. When CNV was allowed to develop for 10 days before treatment was initiated, VEGF Trap not only prevented its further progression, but also induced substantial regression of existing lesions. In addition, VEGF Trap treatment reduced the total lesion volume and largely prevented the progressive leukocyte infiltration and fibrosis associated with CNV.
conclusionsThe subretinal Matrigel CNV model provides a convenient tool for the study of the diverse components of complex CNV lesions. The data not only confirm the critical roles of VEGF in the development and maintenance of CNV, but further demonstrate that VEGF and other VEGF receptor 1 ligands promote CNV-associated inflammation and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.